We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Galectin Therapeutics Inc | NASDAQ:GALT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.04 | -1.19% | 3.33 | 3.33 | 3.35 | 3.48 | 3.28 | 3.39 | 107,770 | 19:37:25 |
Research done in partnership with San Antonio Military Medical Center showed an average 50% PASI reduction by end of 24-week treatment period
The exploratory, open-label, Phase 2a trial enrolled five adult patients with moderate-to-severe plaque psoriasis (PASI ≥ 12 and BSA ≥ 10%) to undergo infusions of 8 mg/kg of GR-MD-02 every other week for 24 weeks (13 infusions total). The primary endpoint of the trial was a reduction in PASI score of 75% (PASI-75) with secondary endpoints measuring adverse events and achieving PASI-50. One patient exceeded the primary endpoint with an 80% reduction in PASI 30 days after their last infusion, while the other four patients reached PASI-50 by their 10th infusion. All five patients completed the treatment phase of the study with no serious adverse events.
“We are pleased by the results of our 24-week psoriasis trial demonstrating the safety and efficacy of GR-MD-02 in patients with moderate to severe plaque psoriasis,” said Peter G. Traber, M.D., president, chief executive officer and chief medical officer, Galectin Therapeutics. “Moreover, the activity of GR-MD-02 in a human disease strongly associated with non-alcoholic steatohepatitis (NASH) and increased galectin-3 expression suggests that our lead compound may also show significant activity in NASH, which remains the company’s primary target.”
About PsoriasisPsoriasis, which manifests most often as plaque psoriasis, is a chronic, relapsing, inflammatory skin disorder. Although plaque psoriasis is rarely life threatening, it often is refractory to treatment. According to the International Federation of Psoriasis Associations, about 3% of the world’s population has some form of psoriasis. In the U.S. there are about 150,000 new cases every year, and psoriasis affects about 2% of the U. S. population, according to the Cleveland Clinic.
About GR-MD-02GR-MD-02 is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of fatty liver disease and fibrosis. Galectin-3 plays a major role in diseases that involve scarring of organs including fibrotic disorders of the liver, lung, kidney, heart and vascular system. The drug binds to galectin proteins and disrupts their function. Preclinical data in animals have shown that GR-MD-02 has robust treatment effects in reversing liver fibrosis and cirrhosis.
About Galectin TherapeuticsGalectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.
Contacts: Jack Callicutt, Chief Financial Officer (678) 620-3186 ir@galectintherapeutics.com
1 Year Galectin Therapeutics Chart |
1 Month Galectin Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions